Literature DB >> 18472121

A new generation of progesterone receptor modulators.

Richard C Winneker1, Andrew Fensome, Puwen Zhang, Matthew R Yudt, Casey C McComas, Rayomond J Unwalla.   

Abstract

Progesterone receptor (PR) modulators have evolved both structurally and mechanistically over the past half-century. Classical steroidal PR agonists continue to play an important role in women's health such as in oral contraception and post-menopausal hormone therapy whereas steroid-based PR antagonists and selective PR modulators are being evaluated clinically in a wide range of gynecologic conditions. This review will focus primarily on the newer generation of PR modulators derived from structurally unique chemical scaffolds. For example, tanaproget (TNPR) is described as a non-steroidal PR agonist with high affinity and selectivity for the PR that is significantly more potent than many of its steroidal counterparts in a variety of pre-clinical efficacy models. Similarly, we present numerous examples of unique non-steroidal PR antagonists in various stages of characterization and development. A basic understanding of the structural determinants for high affinity binding of these new PR modulators to the PR ligand-binding domain (LBD) is also discussed. Finally, as the biology of the PR becomes further defined, we speculate on the future development of novel PR modulators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472121     DOI: 10.1016/j.steroids.2008.03.005

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  8 in total

1.  X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Bert Kazemier; Rolien Bosch; Ross McGuire; Rita Azevedo; Hans Hamersma; Koen Dechering; Arthur Oubrie; Marcel van Duin; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

2.  Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Koen Dechering; Tsang Wai Lam; Angus R Brown; Niall M Hamilton; Olaf Nimz; Rolien Bosch; Ross McGuire; Arthur Oubrie; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

Review 3.  Progestin therapy to prevent preterm birth: History and effectiveness of current strategies and development of novel approaches.

Authors:  Sam A Mesiano; Gregory A Peters; Peyvand Amini; Rachel A Wilson; Gregory P Tochtrop; Focco van Den Akker
Journal:  Placenta       Date:  2019-01-28       Impact factor: 3.481

4.  Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.

Authors:  Hai-Bing Zhou; Jae Hak Lee; Christopher G Mayne; Kathryn E Carlson; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

5.  Development of N-(4-Phenoxyphenyl)benzenesulfonamide Derivatives as Novel Nonsteroidal Progesterone Receptor Antagonists.

Authors:  Ayumi Yamada; Yuko Kazui; Hiromasa Yoshioka; Aya Tanatani; Shuichi Mori; Hiroyuki Kagechika; Shinya Fujii
Journal:  ACS Med Chem Lett       Date:  2016-09-15       Impact factor: 4.345

6.  The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation.

Authors:  Hans C A Raaijmakers; Judith E Versteegh; Joost C M Uitdehaag
Journal:  J Biol Chem       Date:  2009-04-16       Impact factor: 5.157

7.  StackPR is a new computational approach for large-scale identification of progesterone receptor antagonists using the stacking strategy.

Authors:  Nalini Schaduangrat; Nuttapat Anuwongcharoen; Mohammad Ali Moni; Pietro Lio'; Phasit Charoenkwan; Watshara Shoombuatong
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

8.  Oral contraceptive progestins and angiotensin-dependent control of the renal circulation in humans.

Authors:  M A Sarna; N K Hollenberg; E W Seely; S B Ahmed
Journal:  J Hum Hypertens       Date:  2009-01-22       Impact factor: 3.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.